Hepatocellular Carcinoma
GLP-1RA use linked to lower risk for cirrhosis, mortality in MASLD with diabetes
Use of glucagon-like peptide-1 receptor agonists was associated with a reduced risk for progression to cirrhosis and other complications in patients with metabolic dysfunction-associated steatotic liver disease and diabetes, data showed.
Combination prolongs PFS in intermediate-stage hepatocellular carcinoma
The addition of lenvatinib and pembrolizumab to transarterial chemoembolization extended PFS for patients with intermediate-stage hepatocellular carcinoma, according to randomized phase 3 study results.
FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy
The FDA approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection.
Women 8% less likely than men to receive a liver transplant, possibly due to candidate size
Women with hepatocellular carcinoma were less likely to receive a liver transplant and more likely to die or be removed from the waitlist vs. men, underscoring the need for changes to allocation policies, according to researchers.
Even with HCV cure, surveillance for portal hypertension, HCC ‘should be mandatory’
Despite achieving cure with direct-acting antivirals, patients with chronic hepatitis C virus-related decompensated cirrhosis remain at risk for progression of portal hypertension, further decompensation and hepatocellular carcinoma.
Early declines in serum hepatitis B RNA levels may ‘serve as independent predictors’ of HCC
Declines in serum hepatitis B virus RNA at the first and second year of treatment with nucleos(t)ide analogues correlated with risk for hepatocellular carcinoma and may serve as independent predictors of cancer development.
Neoadjuvant immunotherapy may broaden surgery eligibility for hepatocellular carcinoma
Neoadjuvant immunotherapy may allow more people with hepatocellular carcinoma to undergo surgical resection, according to retrospective study results.
Model may ‘serve as a starting point’ to identify patients with MASLD at high risk for HCC
A prediction model could be a “starting point” to identify patients with metabolic dysfunction-associated steatotic liver disease at high risk for hepatocellular carcinoma who may require intervention or surveillance, researchers wrote.
Up-to-date HCC screening after HCV cure improves survival in patients with cirrhosis
Remaining current on screening for hepatocellular carcinoma correlated with a “survival benefit” in older adults with hepatitis C virus-related cirrhosis who achieved viral cure but later developed HCC, according to researchers.
Risk score has ‘superior ability’ to predict LT waitlist dropout among patients with HCC
A continuous risk score accurately predicted waitlist dropout and post-liver transplantation outcomes in patients with hepatocellular carcinoma, even over the course of several UNOS policy changes, researchers reported.